PEMIVIBART (pem iv i bart) reduces the risk of COVID-19. It does not treat COVID-19. It is still possible to get COVID-19 after receiving this medication, but the symptoms may be less severe or not last as long. It works by helping people with a weak immune system fight off a future infection. It is a monoclonal antibody. The FDA has allowed the emergency use of this medication.


There is no lifestyle interaction information available for this medication.